Ob/gyns have welcomed the expanded role of pharmacists in providing quality care to women. The detailed instructions that pharmacists give when dispensing medication reinforce the information we give in the office.
This collegial relationship, however, is now being threatened by the spread of refusal clauses or so-called "conscience clauses" for pharmacists. The Pharmacists for Life International (PFLI) Model Conscience Clause states:
"The rights of conscience of any person being a duly licensed pharmacist, who shall object on personal, ethical, moral, or religious grounds to the performance of any act in the normal course of professional performance or dispensing, shall be respected.
Any such person making such a claim of conscience, or who states a willingness or intention to make such a claim of conscience, shall not be denied employment, or discriminated against in any manner related to employment because of such a claim of conscience."
Such clauses would enable a pharmacist, who generally has limited knowledge of a patient's condition, to refuse to fill prescriptions for FDA-approved drugs and thereby to veto a treatment decision made by a woman and her doctor. Four states (South Dakota, Arkansas, Mississippi, and Georgia) currently allow pharmacists to refuse prescriptions for contraceptives and emergency contraception.
We physicians have tolerated intrusion into the sanctity of the patient-physician relationship in the past to achieve goals that were in the patient's benefit or that did no harm. For example, the codification of the points that must be covered when obtaining a woman's consent for permanent sterilization were designed to protect the woman's right to complete information and to ensure that she has time to consider her choice. When insurance companies limit the drugs they cover, it clearly influences the prescriptions physicians write, but it does not prohibit a woman's access to those medications if she is willing and able to purchase them herself. Pharmacist conscience clauses, however, intrude on the doctor-patient relationship and benefit only the pharmacist.
Conscience clauses give pharmacists the power to override patients' rights and physicians' orders without having to bear any responsibility for the consequences of their actions (or inaction). A pharmacist who does not believe in dispensing oral contraceptives cannot be disciplined for his or her refusal to provide pills when a customer conceives. What is next? Will this right to refuse service be extended to methotrexate to treat ectopic pregnancies? There is no provision that the pharmacist's beliefs be evidence-based.
In 2004, 23 states considered legislation to expand conscience clause laws pertaining to the refusal of individuals or entities to provide services related to contraception or abortion.2 This year, similar legislation has already been introduced in eight states. On the other side of the coin is the Access to Legal Pharmaceuticals Act (S.809), now awaiting action by the Senate, which would "establish certain duties for pharmacies when pharmacists employed by the pharmacies refuse to fill valid prescriptions for drugs or devices on the basis of personal beliefs, or for other purposes,"3 and four states are considering bills to require pharmacists to fill all legal drug orders. One state is considering bills of both types.
What can we do? We need to add balance to the discussion and help lawmakers understand that this is not just an issue of religious freedom; it is an issue of patient rights and privacy. The safety and efficacy of drugs is established by the FDA. Prescribing is done by licensed health-care providers. Pharmacists have a professional responsibility to ensure that the prescriptions brought to them are filled.
REFERENCES
1. Pharmacist's Model Conscience Clause. Pharmacists for Life International. Accessed 6/12/05 at http:// http://www.pfli.org/main.php?pfli=modelpharmacistcc.
2. Robeznieks A. Battle of the conscience clause: When practitioners say no. Am Med News. April 11, 2005. Accessed 6/12/05 at http:// http://www.ama-assn.org/amednews/2005/04/11/prsa0411.htm (AMA members).
3. Introduction of the Access to Legal Pharmaceuticals Act. 109th Congress. 1st Session. S.809. Accessed 6/14/05 at http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=109_cong_bills&docid=f:s809is.txt.pdf.
Unlocking HPV prevention: Insights from 2022 data on vaccination trends
May 14th 2024Explore the latest findings revealing vaccination rates among children aged 9 to 17 years, uncovering demographic disparities and highlighting the crucial role of vaccination in combating human papillomavirus infections and related health risks.
Read More
Prenatal cannabis and nicotine use linked to adverse pregnancy outcomes
May 14th 2024A recent study highlights the heightened risks of maternal and neonatal morbidity and mortality associated with combined cannabis and nicotine use during pregnancy, urging further investigation into their impact on short- and long-term outcomes.
Read More
Understanding pediatric STIs: Trends, management, and more
May 10th 2024Dive into the rising prevalence of sexually transmitted infections among adolescents and young adults, exploring educational gaps, vaccination rates, and the imperative need for open conversations between patients and health care providers to combat stigma and enhance preventive care.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More